In the last trading session, 0.51 million shares of the 10x Genomics Inc (NASDAQ:TXG) were traded, and its beta was 2.00. Most recently the company’s share price was $9.48, and it changed around -$0.37 or -3.76% from the last close, which brings the market valuation of the company to $1.16B. TXG currently trades at a discount to its 52-week high of $45.60, offering almost -381.01% off that amount. The share price’s 52-week low was $9.77, which indicates that the current value has fallen by an impressive -3.06% since then.
10x Genomics Inc stock received a consensus recommendation rating of Hold, based on a mean score of 2.47. If we narrow it down even further, the data shows that 0 out of 17 analysts rate the stock as a Sell; another 2 rate it as Overweight. Among the rest, 9 recommended TXG as a Hold, whereas 5 deemed it a Buy, and 1 rated it as Underweight. 10x Genomics Inc is expected to report earnings per share of -0.29 for the current quarter.
10x Genomics Inc (NASDAQ:TXG) trade information
Instantly TXG has showed a red trend with a performance of -3.76% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 11.90 on recent trading dayincreased the stock’s daily price by 20.34%. The company’s shares are currently down -33.98% year-to-date, but still down -14.67% over the last five days. On the other hand, 10x Genomics Inc (NASDAQ:TXG) is -36.80% down in the 30-day period.
The consensus price target as assigned by Wall Street analysts is $25, which translates to bulls needing to increase their stock price by 62.08% from its current value. Analyst projections state that TXG is forecast to be at a low of $24 and a high of $46.
10x Genomics Inc (TXG) estimates and forecasts
The year-over-year growth rate is expected to be 0.30%, up from the previous year.
Consensus estimates provided by 15 financial analysts predict the company will bring in an average of 133.55M in revenue for the current quarter. 15 analysts expect 10x Genomics Inc to make 146.4M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 141.01M and 153.1M respectively. Analysts predict that the company’s current quarter sales will drop, forecast at -5.29%. Forecasts for the next quarter put sales growth at -4.38%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -36.10%. 10x Genomics Inc earnings are expected to increase by 1.75% in 2025, but the outlook is positive 17.47% per year for the next five years.
10x Genomics Inc (NASDAQ:TXG)’s Major holders
VANGUARD GROUP INC, with 8.5341% or 10.19 million shares worth $198.18 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
ARK ETF Tr-ARK Innovation ETF and Vanguard Total Stock Market Index Fund were the top two Mutual Funds as of Dec 31, 2024. The former held 8.25 shares worth $78.63 million, making up 7.62% of all outstanding shares. On the other hand, Vanguard Total Stock Market Index Fund held roughly 3.25 shares worth around $30.95 million, which represents about 3.00% of the total shares outstanding.
